ArticleMaterials today. Bio2026
Functional matrix engineering enables aggregate-state photophysics in tumor-responsive organic NIR-II phototheranostics.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organic NIR-II phototheranostic nanoparticles function as molecular assemblies, making their optical performance fundamentally dependent on aggregate-state photophysics governed by intermolecular organization. However, exploiting the matrix to actively program intermolecular organization during nanoparticle assembly remains largely unexplored. Here, we establish functional matrix engineering as a practical implementation of assembly engineering, in which tumor-microenvironment-responsive prodrugs serve as multifunctional matrix components that reorganize intermolecular packing to enhance aggregate-state photophysics while simultaneously enabling therapeutic activation. A benzobisthiadiazole (BBT)-based D-A-A-D fluorophore (2A895) was co-assembled with two tumor-microenvironment-responsive prodrugs (CPB and Dyl) serving as multifunctional matrix components. Molecular dynamics simulations reveal that the functional matrix reorganizes intermolecular packing by disrupting compact π-π contacts, and indicates reduced electronic coupling through enlarged centroid separation and non-parallel packing, thereby suppressing aggregation-caused quenching and enhancing NIR-II fluorescence without compromising photothermal conversion. Meanwhile, the stimulus-responsive matrix enables H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.